JP2016112562A - 水素含有生体適用液の製造装置 - Google Patents
水素含有生体適用液の製造装置 Download PDFInfo
- Publication number
- JP2016112562A JP2016112562A JP2016008538A JP2016008538A JP2016112562A JP 2016112562 A JP2016112562 A JP 2016112562A JP 2016008538 A JP2016008538 A JP 2016008538A JP 2016008538 A JP2016008538 A JP 2016008538A JP 2016112562 A JP2016112562 A JP 2016112562A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- container
- application liquid
- generation system
- packaging material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 185
- 239000001257 hydrogen Substances 0.000 title claims abstract description 150
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 150
- 239000007788 liquid Substances 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000005022 packaging material Substances 0.000 claims abstract description 29
- 230000035699 permeability Effects 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 12
- 239000004745 nonwoven fabric Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- 239000013060 biological fluid Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000003860 storage Methods 0.000 abstract description 6
- 238000009826 distribution Methods 0.000 abstract description 5
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 37
- 229910052782 aluminium Inorganic materials 0.000 description 35
- 239000002504 physiological saline solution Substances 0.000 description 21
- 239000011575 calcium Substances 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 229910052751 metal Inorganic materials 0.000 description 16
- -1 lipid peroxides Chemical class 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000007872 degassing Methods 0.000 description 9
- 229920000573 polyethylene Polymers 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 5
- 239000000920 calcium hydroxide Substances 0.000 description 5
- 235000011116 calcium hydroxide Nutrition 0.000 description 5
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000000292 calcium oxide Substances 0.000 description 3
- 235000012255 calcium oxide Nutrition 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000002824 redox indicator Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003230 hygroscopic agent Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/22—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by diffusion
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/02—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen
- C01B3/06—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B3/00—Hydrogen; Gaseous mixtures containing hydrogen; Separation of hydrogen from mixtures containing it; Purification of hydrogen
- C01B3/02—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen
- C01B3/06—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents
- C01B3/10—Production of hydrogen or of gaseous mixtures containing a substantial proportion of hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents by reaction of water vapour with metals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Combustion & Propulsion (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』,本発明の生体適用液11が収納された容器12に相当するので、以下符号12で示す)と、金属カルシウム0.5g(関東化学社製:『カルシウム』)を不織布で包むことで得られた本発明の水素発生系13を、アルミバッグ(ハギオス社製:『MZ−05』,本発明の包装材14に相当するので、以下符号14で示す)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、金属カルシウム0.5g(関東化学社製:『カルシウム』)を不織布で包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールし、恒温恒湿器(エスペック社製『LU−113』、槽温:60℃)に放置することで室温より高い温度環境にアルミバッグ14を保持した。そして、48時間後にアルミバッグ14を恒温恒湿器から取り出し、生理食塩液11の溶存水素濃度をDHメーターで測定した。
外側をポリプロピレン製の外装袋で覆われた、腹膜透析液2000mLが収容されたポリプロピレン製の腹膜透析液バッグ12(テルモ社製『ミッドペリックL135』)と、金属カルシウム3g(関東化学社製:『カルシウム』)を不織布で包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで腹膜透過バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールし、恒温恒湿器(エスペック社製『LU−113』、室温:60℃)に放置することで室温より高い温度環境にアルミバッグ14を保持した。そして、5日後にアルミバッグ14を恒温恒湿器から取り出し、腹膜透析液11の溶存水素濃度をDHメーターで測定した。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、不織布に包まれた金属カルシウム0.5g(関東化学社製:『カルシウム』)13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気することなくそのままヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)をアルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、アルミバッグ14に、水素発生系13に代えて1.6mg/Lの飽和濃度の水素溶存水を満たしてヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、金属マグネシウム0.4g(関東金属社製:『マグネシウム粉末 Mg100』)と陽イオン交換樹脂0.2g(三菱化学社製:『ダイヤイオン FMK10』)を不織布に包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、水素化カルシウム0.5g(和光純薬工業社製:『水素化カルシウム』)を不織布に包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、金属アルミニウム0.4g(ミナルコ社製:『アルミニウム粉末』)、陽イオン交換樹脂0.2g(同上)、及び塩化カルシウム0.1g(和光純薬工業社製:『塩化カルシウム』)を不織布に包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグをヒートシールした。
生理食塩液500mLが収容されたポリエチレン製の輸液バッグ12(大塚製薬社製:『日本薬局方生理食塩液 大塚生食注』)と、金属アルミニウム0.4g(同上)、水酸化カルシウム0.15g(和光純薬工業社製:『水酸化カルシウム』)、及び塩化カルシウム0.1g(同上)を不織布に包むことで得られた本発明の水素発生系13を、アルミバッグ14(ハギオス社製:『MZ−05』)で被覆した後、脱気シーラー(タカトテクニカ社製:『VP−300』)を用いて−0.1Mpaで輸液バッグ12とアルミバッグ14との間の空間15の体積を減じながらアルミバッグ14をヒートシールした。
実施例1〜3と比較例1との結果から、実施例1〜3のように容器12と包装材14との間の空間15を脱気することで、24時間後の溶存水素濃度DHが0.06mg/Lであったものが3週間後まで増加することが確認された。これに対して、容器12と包装材14との間の空間15を脱気しない比較例では、24時間後の溶存水素濃度DHが0.03mg/Lと低く、しかも3週間後の溶存水素濃度DHに至っては、実施例1の0.77mg/Lに対してDH=0.29mg/Lと明らかな増加の差が確認された。
11…生体適用液
12…容器
13…水素発生系
14…包装材
15…空間
16…第2容器
Claims (3)
- 生体適用液が収納された水蒸気透過性を有する容器と、
水分により水素を発生させる水素発生系と、
前記容器と前記水素発生系とを被覆する水素分子透過性の低い包装材と、を備える水素含有生体適用液の製造装置であって、
前記包装材が、前記容器と前記容器の外側に位置する水素発生系を被覆し、かつ、前記容器と前記包装材との間の空間の湿度を高める処理が施され、
前記水素発生系が、水素発生反応促進剤を含む水素含有生体適用液の製造装置。 - 前記水素発生系に防熱処理が施されている請求項1に記載の水素含有生体適用液の製造装置。
- 前記防熱処理が、不織布で覆うという防熱処理である請求項2に記載の水素含有生体適用液の製造装置。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014050115 | 2014-03-13 | ||
| JP2014050115 | 2014-03-13 | ||
| JP2014227296 | 2014-11-07 | ||
| JP2014227296 | 2014-11-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015543189A Division JP5935954B2 (ja) | 2014-03-13 | 2015-03-13 | 水素含有生体適用液の製造方法及びそのための外装体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016112562A true JP2016112562A (ja) | 2016-06-23 |
Family
ID=54072551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015543189A Active JP5935954B2 (ja) | 2014-03-13 | 2015-03-13 | 水素含有生体適用液の製造方法及びそのための外装体 |
| JP2016008538A Pending JP2016112562A (ja) | 2014-03-13 | 2016-01-20 | 水素含有生体適用液の製造装置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015543189A Active JP5935954B2 (ja) | 2014-03-13 | 2015-03-13 | 水素含有生体適用液の製造方法及びそのための外装体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9636358B2 (ja) |
| EP (1) | EP2985028B1 (ja) |
| JP (2) | JP5935954B2 (ja) |
| KR (1) | KR101653937B1 (ja) |
| CN (1) | CN105246492B (ja) |
| WO (1) | WO2015137499A2 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016122768A1 (de) * | 2015-12-02 | 2017-06-14 | Miz Company Limited | Vorrichtung und Verfahren zum Erzeugen einer wasserstoffhaltigen Flüssigkeit |
| JP6170605B1 (ja) * | 2016-10-27 | 2017-07-26 | MiZ株式会社 | 水素含有液体の製造方法 |
| CN106829027A (zh) * | 2016-12-30 | 2017-06-13 | 于攀 | 一种含氢气无菌液体的快速制备方法及装置 |
| CN107281214A (zh) * | 2017-06-06 | 2017-10-24 | 北京工业大学 | 氢分子液体/气体在制备抑制肿瘤干细胞药物中的应用 |
| CN108941600A (zh) * | 2018-07-09 | 2018-12-07 | 宁波中科科创新能源科技有限公司 | 纳米铂胶体制备方法和氢分子浓度指示剂制备方法 |
| CN109362704A (zh) * | 2018-09-20 | 2019-02-22 | 中国人民解放军第二军医大学第二附属医院 | 一种可自动释放氢离子的离体断肢保存袋 |
| JP6890353B2 (ja) * | 2019-03-26 | 2021-06-18 | MiZ株式会社 | 分子状水素を含む腎臓疾患の腎機能改善のための組成物 |
| DE102019112844A1 (de) * | 2019-05-16 | 2020-11-19 | Viawa GbR (vertretungsberechtigter Gesellschafter: Markus Johannes Friedrich-Wilhelm Pohlhausen, 53773 Hennef) | Verfahren und Verpackung zum Konservieren eines Lebensmittels in einer Wasserstoffatmosphäre |
| JP6905108B1 (ja) | 2020-02-03 | 2021-07-21 | 株式会社日本トリム | 水素付加装置及び水素付加方法 |
| JP2021151980A (ja) * | 2020-03-24 | 2021-09-30 | MiZ株式会社 | 脳炎および/または髄膜炎と当該脳炎および/または髄膜炎に関連する症状を予防および/または改善するための分子状水素含有組成物 |
| US12473658B2 (en) | 2024-02-02 | 2025-11-18 | TegIpco, LLC | Power conversion systems and methods |
| US12476552B1 (en) | 2025-02-21 | 2025-11-18 | Teglpco, LLC | AC current source and method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624794A (en) * | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
| JPH11262514A (ja) * | 1998-03-17 | 1999-09-28 | Otsuka Pharmaceut Factory Inc | 重炭酸塩含有薬液容器包装体及び炭酸ガス分圧コントロール剤 |
| JP2003313001A (ja) * | 2002-02-22 | 2003-11-06 | Iwatani Internatl Corp | 水素発生方法及び水素発生装置 |
| JP2005161209A (ja) * | 2003-12-03 | 2005-06-23 | Hidemitsu Hayashi | 水素豊富水生成方法及び水素豊富水生成器 |
| JP2011177242A (ja) * | 2010-02-26 | 2011-09-15 | Mizu Kk | 水素含有生体適用液の製造方法及び製造装置 |
| WO2012053472A1 (ja) * | 2010-10-18 | 2012-04-26 | ミズ株式会社 | 生体適用液への水素添加器具 |
| JP2013163135A (ja) * | 2010-10-25 | 2013-08-22 | Mizu Kk | 生体適用液への選択的水素添加器具 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3419400A (en) * | 1965-10-22 | 1968-12-31 | Swift & Co | Packaging foods-production of oxygen-free packages |
| US4437567A (en) | 1982-01-27 | 1984-03-20 | The Kendall Company | Sterile package and method of making |
| US4857409A (en) * | 1985-02-08 | 1989-08-15 | Exxon Chemical Patents Inc. | Clear barrier composites containing polyisobutylene/polyolefin alloy components |
| US5789151A (en) * | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
| US6877601B1 (en) * | 1998-10-29 | 2005-04-12 | Tres Fresh L.L.C. | Packaging system for extending the shelf life of moisture-containing foods |
| US20040067182A1 (en) * | 2002-10-08 | 2004-04-08 | Kelly Robert Charles | Gas-release packet |
| WO2004113224A1 (en) * | 2003-06-16 | 2004-12-29 | Selective Micro Technologies, Llc | Reusable apparatus for gas generation |
| JP2005097358A (ja) | 2003-09-22 | 2005-04-14 | Showa Denko Plastic Products Co Ltd | ポリプロピレン系成形体及び容器 |
| JP4653945B2 (ja) * | 2003-10-24 | 2011-03-16 | ミズ株式会社 | 薬理機能水、およびその用途 |
| US20080078404A1 (en) * | 2006-09-29 | 2008-04-03 | Nellcor Puritan Bennett Incorporated | Endotracheal cuff and technique for using the same |
| JP4967001B2 (ja) * | 2009-03-13 | 2012-07-04 | ミズ株式会社 | 水素含有生体適用液の製造方法、及びそのための装置 |
| JP4652479B1 (ja) * | 2010-07-14 | 2011-03-16 | ミズ株式会社 | 生体適用液への選択的水素添加器具 |
| US8597264B2 (en) | 2011-03-24 | 2013-12-03 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
| WO2013157657A1 (ja) * | 2012-04-20 | 2013-10-24 | 株式会社プロジェクトジャパン | 気密性に優れた容器及び容器のガス分子または揮発成分の保持方法 |
| JP6028182B2 (ja) * | 2012-07-06 | 2016-11-16 | 株式会社光未来 | 水素ガスの密封袋、及び水素ガスの溶解方法 |
-
2015
- 2015-03-13 EP EP15760863.9A patent/EP2985028B1/en active Active
- 2015-03-13 CN CN201580000856.1A patent/CN105246492B/zh active Active
- 2015-03-13 JP JP2015543189A patent/JP5935954B2/ja active Active
- 2015-03-13 KR KR1020157033926A patent/KR101653937B1/ko not_active Expired - Fee Related
- 2015-03-13 US US14/891,851 patent/US9636358B2/en not_active Expired - Fee Related
- 2015-03-13 WO PCT/JP2015/057553 patent/WO2015137499A2/ja not_active Ceased
-
2016
- 2016-01-20 JP JP2016008538A patent/JP2016112562A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624794A (en) * | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
| JPH11506777A (ja) * | 1995-06-05 | 1999-06-15 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 酸素除去による冷凍赤血球の有効貯蔵寿命の延長方法 |
| JPH11262514A (ja) * | 1998-03-17 | 1999-09-28 | Otsuka Pharmaceut Factory Inc | 重炭酸塩含有薬液容器包装体及び炭酸ガス分圧コントロール剤 |
| JP2003313001A (ja) * | 2002-02-22 | 2003-11-06 | Iwatani Internatl Corp | 水素発生方法及び水素発生装置 |
| JP2005161209A (ja) * | 2003-12-03 | 2005-06-23 | Hidemitsu Hayashi | 水素豊富水生成方法及び水素豊富水生成器 |
| JP2011177242A (ja) * | 2010-02-26 | 2011-09-15 | Mizu Kk | 水素含有生体適用液の製造方法及び製造装置 |
| WO2012053472A1 (ja) * | 2010-10-18 | 2012-04-26 | ミズ株式会社 | 生体適用液への水素添加器具 |
| JP2013163135A (ja) * | 2010-10-25 | 2013-08-22 | Mizu Kk | 生体適用液への選択的水素添加器具 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2985028B1 (en) | 2019-05-22 |
| US9636358B2 (en) | 2017-05-02 |
| US20160089394A1 (en) | 2016-03-31 |
| KR20150139632A (ko) | 2015-12-11 |
| EP2985028A2 (en) | 2016-02-17 |
| CN105246492B (zh) | 2017-09-29 |
| KR101653937B1 (ko) | 2016-09-02 |
| JPWO2015137499A1 (ja) | 2017-04-06 |
| EP2985028A4 (en) | 2016-06-29 |
| JP5935954B2 (ja) | 2016-06-15 |
| CN105246492A (zh) | 2016-01-13 |
| WO2015137499A3 (ja) | 2015-11-05 |
| WO2015137499A2 (ja) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5935954B2 (ja) | 水素含有生体適用液の製造方法及びそのための外装体 | |
| TWI389681B (zh) | And a manufacturing apparatus for producing a suitable liquid for a living body containing hydrogen | |
| JP5266267B2 (ja) | 水素含有生体適用液の製造方法及び製造装置 | |
| JP4216199B2 (ja) | 透析液用の複数区画を備えたバッグアセンブリ | |
| CN102249041A (zh) | 溶解有活性氢分子的水的储存容器和供给装置 | |
| KR20070109924A (ko) | 중탄산염 용액이 충전된 용기용 수납체 | |
| TW201021851A (en) | Total nutrition infusion solution | |
| JP6170605B1 (ja) | 水素含有液体の製造方法 | |
| JP3243387B2 (ja) | 炭酸水素塩含有薬液入りプラスチック容器の収納体 | |
| JP6607647B2 (ja) | 水素含有液体の生成装置及び方法 | |
| TWI574685B (zh) | A method for producing a suitable liquid for living organisms containing hydrogen, and an external preparation for the liquid | |
| JP3375518B2 (ja) | 注射剤 | |
| JP3733583B2 (ja) | 重炭酸塩含有薬液充填容器包装体 | |
| JPWO2019093493A1 (ja) | 飲料用水素含有水製品並びに箱詰めキット | |
| WO2020204170A1 (ja) | 重炭酸イオンを含有する心筋保護液の収容体、及びその製造方法 | |
| CN104822394B (zh) | 由酯类树脂制成的医疗器械的灭菌方法 | |
| TWI664141B (zh) | 含氫液體的產生裝置、產生方法以及產生套組 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180313 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190729 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190729 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200107 |